BioSpace News Archive

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the first patient has been dosed in a Phase 1a/1b study of IBI319, an anti-PD-1/CD137 bispecific antibody.

SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), today announced the signing of an agreement that subject to an approval by the Food & Drug Administration (FDA), will allow AZOVA to sell and distribute SQI’s COVID-19 HOME Antibody Test .

The liquid biopsy market was valued at US$ 3,861.49 million in 2019and is projected to reach US$ 8,123.85 million by 2027; it is expected to grow at a CAGR of 9.9% during 2020–2027.

LENSAR, Inc. today announced a total of 12 abstracts highlighting LENSAR’s technology have been accepted for presentation at the 2021 Annual Meeting of the American Society of Cataract and Refractive Surgery.

- Uncontrolled blood reflux leads to serious patient safety issues like thrombotic occlusions and infection - Only needleless connectors with bidirectional flow control - like Nexus TKO - can automatically prevent blood reflux, consistent with the 2021 INS Standards

CANbridge Pharmaceuticals Inc. announced that the Chinese National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for CAN106, a long-acting humanized monoclonal antibody targeting complement C5 of the complement system.

NLS Pharmaceutics Ltd. announces that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug application

Today, the Ingredient Transparency Center’s Collagen Stewardship Alliance (CSA) announced that BioCell Technology, LLC has signed on as a Sponsor Level supporter.

ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its second quarter 2021 financial results.

Clarus and Lipocine (NASDAQ: LPCN) agreed to settle all outstanding claims in the patent infringement lawsuit brought against Clarus by Lipocine and to further resolve a patent interference between the parties.